KALA BIO (NASDAQ:KALA – Get Free Report) and Trevena (NASDAQ:TRVN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.
Valuation and Earnings
This table compares KALA BIO and Trevena’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KALA BIO | $3.89 million | 4.43 | -$42.20 million | ($15.15) | -0.40 |
| Trevena | $3.12 million | 25.97 | -$40.29 million | ($2.68) | -1.42 |
Trevena has lower revenue, but higher earnings than KALA BIO. Trevena is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Profitability
This table compares KALA BIO and Trevena’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KALA BIO | N/A | -366.43% | -66.41% |
| Trevena | N/A | -1,018.15% | -105.93% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for KALA BIO and Trevena, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KALA BIO | 0 | 0 | 2 | 0 | 3.00 |
| Trevena | 0 | 0 | 1 | 0 | 3.00 |
KALA BIO currently has a consensus target price of $16.50, indicating a potential upside of 169.61%. Trevena has a consensus target price of $125.00, indicating a potential upside of 3,189.47%. Given Trevena’s higher possible upside, analysts clearly believe Trevena is more favorable than KALA BIO.
Insider and Institutional Ownership
24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 13.4% of KALA BIO shares are owned by insiders. Comparatively, 2.4% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
KALA BIO beats Trevena on 7 of the 12 factors compared between the two stocks.
About KALA BIO
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
About Trevena
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
